WO2008123788A1

WO2008123788A1 - USE OF Enterococcus faecium M AND Enterococcus faecium M-3185 STRAINS FOR ENHANCING GLYCOLYSIS RATE AND A GLYCOLYSIS RATE INCREASING METHOD

Info

Publication number: WO2008123788A1
Application number: PCT/RU2007/000162
Authority: WO
Inventors: Alexei Nikolaevich Parfenov
Original assignee: Alexei Nikolaevich Parfenov
Priority date: 2007-04-05
Filing date: 2007-04-05
Publication date: 2008-10-16

Abstract

The invention relates to a method for using Enterococcus faecium M (VKPM B-3490) and Enterococcus faecium M-3185 (VKPM B-3491) strains, a composition and a preparation 'Bilactine' based thereon for enhancing a glycolysis rate in somatic cells. Glycolysis rate enhancing methods are also disclosed.

Description

The use of strains of Epterososs faeciit M and Epterosossi faeciit M-3185 to increase the rate of glycolysis and a method of increasing the rate of glycolysis

Technical field

The invention relates to the field of medicine and biotechnology, namely to the use of strains of Epterosossi faesite M VKPM (B-3490) and Epterosossi faesiit M-3185 (VKPM B-3491), compositions and preparations based on them to increase the speed of glycolysis (glycolytic energy production).

State of the art

Discloses the use of vanadium compounds for the activation of glycolysis (UDC 616.379-003.64-092-074. "BAHADIYCODEPZHASCHIE COEAHHEHI-M - A NEW CLASS OF THERAPEUTIC AGENTS FOR TREATING DIABETES DIABETA" H.F BELYAEVA, VK Gorodetsky, AI Tochilkin, GOLUBEV MA, N.V. SEMENOVA, I.R. KOVELMAN Research Institute of Biomedical Chemistry F 'AMS 119832, Moscow, 10 Pogodinskaya St.)

It is known to use an implant made of titanium nickelide as a means of intensifying the energy supply of lymphocytes due to anaerobic glycolysis (BULLETIN WITH RAMS, Ш2 (116), 2005 UDC: 611-018.74: 616.314-089.843] - 07: 616.155.32-008.1 A. G. Loginov ((STATE OF ENERGY METABOLISM OF LYMPHOCYTES OF REGIONAL LYMPHATIC NODE IN IMPLANTATION OF TITHA NIKELID »GOU Novosibirsk State Medical Academy of the Ministry of Health of the Russian Federation, State Research Institute of Clinical and Experimental Lymphology SB RAMS)

Thyroxine known to use anaerobic energy production to increase in myeloid cells of bone marrow and blood neutrophils (UDC 591.111.1: 577.17: 577,121 "BLIYAHIE thyroxin on activity of some enzymes of energy metabolism in myeloid cells of bone marrow and blood neutrophiles POPOCYATH» .O BABICH ^1, T. .L. ANTONYAK ² , M.F. TYMOCHKO ¹ ^[ Lviv State Medical University, Ukraine, 290010 Lviv, st. Bakery 69.

² Institute of Agriculture and Animal Biology YAAH, Ukraine, 290034 Lviv, 38 V. Stus Street)

It is known that the use of strains of Epterososs faeciitis (Stertossoss faeciitis) and compositions based on them containing these strains as an immunostimulating agent increase the immune status and resistance to viral diseases, resistance to stress (PC17RU96 / 00132).

It is known to use strains of Epiterososs faesite for the treatment of liver failure, for the regeneration of the liver and the intensification of metabolic processes in the liver (PCT / RUOZ / 00386). -

The present invention is aimed at creating a new way to increase the speed of glycolysis (glycolytic energy production) by introducing into the composition of medical preparations the strains of Epterosossis faesite M VKPM (B-3490) and Enterosossis faesit M-3185 (VKPM B-3491), their composition and preparation Bilactin ”based on them, and the use of strains, compositions and a preparation based on them for a new purpose.

SUMMARY OF THE INVENTION

The authors unexpectedly discovered the effectiveness of previously known strains of Epterososs faiesite M (VKPM B-3490) and Epterossoss faecite M-3185 (VKPM B-3491) and the previously known composition as a means of increasing the speed of glycolysis (glycolytic energy production).

The present invention provides for the use of strains of Epterosossis faesite M (VKPM B-3490) and Epterosossis faesiit M-3185 (VKPM B-3491), the composition, means and preparation "Bilactin" based on them to increase the speed of glycolysis (glycolytic energy production).

The invention also provides a method for increasing the rate of glycolysis (glycolytic energy production). Disclosure of the invention

Glycolysis is one of the two main mechanisms of energy supply for the vital activity of human and animal cells. For some cells (for example, mature red blood cells), this is the only energy supply mechanism. For leukocyte cells in the active state, as well as for “fast” skeletal muscle cells, glycolysis is the prevailing energy supply mechanism. Serious diseases such as type 1 and type 2 diabetes mellitus are associated with impaired glycolysis. In connection with the significance of this issue, a significant number of studies have been carried out with the aim of developing methods and means of activating and accelerating the process of glycolysis (glycolytic energy production) by somatic cells.

As a result of the study, the effect of the oral administration of the strains of Epterosossis faesit M (VKPM B-3490) and Epterosossis faesit M-3185 (VKPM B-3491) and the drug “Bilaktin” on the indicators of maximum anaerobic performance (a bicycle ergometric test is very significant) power and power of single movement. The increase in the indicated power reached a phenomenally high level - 40% in 52 days of using the drug. At the same time, the training load during the period of use of the drug and for the previous several months did not undergo significant changes and did not include special exercises for the development of maximum anaerobic performance in bicycle ergometric load.

The data obtained show a direct relationship between the growth of the developed capacity and the increase in the level of lactate in the blood after performing a short-term load. Thus, the obtained phenomenon is based on the increase in the speed of the glycolytic enzyme system of skeletal muscle and glycolytic energy production induced by the strains and the drug “Bilactin” when taken orally.

The drug "Bilactin" (certificate of state registration N ° 77.99.23.3.U12813.11.05 of 07.11.2005) is available in the form of capsules containing:

freeze-dried microbial mass of Epterososs up to 60% faecium M (VKPM B-3490) freeze-dried microbial mass of Epterosossus up to 60% faecium M-3185 (VKPM B-3491) residual amount of soluble solids of the medium up to 20% cultivation

The invention is further illustrated by an example, which is preferred, is intended only to confirm the feasibility of the invention and should not be the basis for limiting the scope of claims of the Applicant. A person skilled in the art will easily find the possibilities of other embodiments of the invention, of course, subject to the claims of the Applicant, as reflected in the claims below.

Example 1

In 2006, an athlete was tested at the VNIIFK Moscow comprehensive examination center for the level of developed maximum power in short-term physical activity (30 seconds) before, on the background, and after 52-yx daily intake of Bilactin with determination of blood lactate level after performing physical activity.

Conclusion of the Center for Comprehensive Examination VNIIFC Athlete N Specialization - power extreme sports, bodybuilding; qualification - MCMK (experience - 17 years).

Age - 33 g. (January 28, 73), body length - 176 cm, body weight - 107.7 kg (10/19/06), 106.0 kg (11/13/06), 110,0 kg (12/12/06)

Results of a comprehensive biomedical examination Load model: maximum anaerobic test (LVipate)

Table 1 Anaerobic Performance

The positive dynamics of anaerobic performance was revealed by the criterion of power and growth of speed-strength potential.

Industrial applicability

The strains of Epterosossis faesite M (VKPM B-3490) and Epterosossis faesiit M-3185 (VKPM B-3491), the composition of strains of Epterosossi faesit M (VKPM B-3490) and Epterosossi M-31pit-34eci "and once the methods used to accelerate the process of glycolysis (glycolytic energy production) can be applied to accelerate the process of glycolysis in somatic cells.

Claims

Claim

1. The use of strain Epterosossis faesite M (VKPM B-3490) for the production of agents to accelerate the process of glycolysis in somatic cells.

2. The use of strain Epterosossis faesite M-3185 (VKPM B-3491) for the production of agents to accelerate the process of glycolysis in somatic cells.

3. The use of strains of Epterososs faesite M (VKPM B-3490) and Epterosossi faecite M-3185 (VKPM B-3491) for the production of agents for accelerating the process of glycolysis in somatic cells.

4. The use of a composition based on the strains of Epterososs faecite M (VKPM B-3490) and / or Epterossoss faeciit M-3185 (VKPM B-3491) to accelerate the glycolysis process in somatic cells.

5. The use of strains of Epterososs faesi M (VKPM B-3490) and Epterosossi faesi M-3185 (VKPM B-3491) for the production of the drug "Bilactin" containing the microbial mass of Epterosossi faesi M (VKPM B-3490%) , the microbial mass of Epiterososs faesite M-3185 (BKPMB-3491) in an amount of 40-60% and the residual amount of soluble substances of the growth medium in an amount of up to 20% to accelerate the glycolysis process in somatic cells.

6. The use of strains of Epterosossis faesite M (VKPM B-3490) and Epterosossis faesiit M-3185 (VKPM B-3491) to accelerate the process of glycolysis in somatic cells, which consists in the oral administration of a composition, agent or preparation based on strains of Epterosossitis Mcfaciositis B (34 VKPM B-3490) -3490) and / or Epterosossis faesite M-3185 (VKPM B-3491) in an effective single dose one to three times a day for 10-180 days.

7. A method of accelerating the process of glycolysis in somatic cells, comprising administering to a patient a strain of Epterosossi, a composition or agent containing a strain of Epterosossi, in an amount effective to accelerate the process of glycolysis in somatic cells, according to which said Epterosossiis strain is selected from the group consisting of Epterosossiis faecite M strain (VKPM B-3490), Epterosossi fecesi M strain (VKPM B-3491) and combinations thereof.

8. The method according to p. 7, in which the patient is introduced a strain of Epterosossis faesite M (VKPM B-3490), a composition or agent containing a strain of Epterosossis faeciit M (VKPM B-3490).

9. The method according to p. 7, in which the patient is introduced a strain of Epterosossis feces M (VKPM B-3491), a composition or agent containing a strain of Epterosossis fecesi M (VKPM B-3491).

10. The method according to p. 7, in which both strains of Epterosossis faesit M (VKPM B-3490) and Epterosossis faecit M (VKPM B-3491), a composition or agent containing both strains of Epterosossic faeciit M (VKPM B-34) are administered and Epterosossia faesite M (VKPM B-3491).

11. The method according to p. 10, in which the patient is administered a composition containing the bacterial mass of the strain Epterosossis faesite M (VKPM B-3490) in an amount of up to 60%, the bacterial mass of the strain Epterosossi faesiit M (VKPM B-3491) in an amount of up to 60% and up to 20% soluble substances of the growing medium.

12. The method of claim. 7, wherein the patient is administered a composition comprising the strain Epterosossis, a single dose of at least 10 ^minutes CFU one to three times a day for 10 to 180 days.

13. A tool for accelerating the process of glycolysis in somatic cells, comprising an effective amount of the strain Epterosossis faesite M (VKPM B-3490) and / or the strain Epterosossis faeciit M-3185 (VKPM B-3491) and a pharmaceutically acceptable carrier.